What Neok Bio does

NEOK Bio is a clinical-stage oncology therapeutics company developing bispecific antibody drug conjugates (ADCs) for the treatment of solid tumor cancers. Founded in 2025 and headquartered in Palo Alto, California as a U.S. subsidiary of Korean biotech ABL Bio, the company is focused on dual-targeting ADC strategies designed to improve safety and efficacy relative to conventional monovalent ADCs. Its lead pipeline consists of two candidates: NEOK001, a B7-H3/ROR1 bispecific ADC, and NEOK002, an EGFR/MUC1 bispecific ADC, both targeting thoracic, gastrointestinal, and gynecological cancers sensitive to Topo-1 inhibition. Initial clinical data is expected in 2027.

The company's technology stack is anchored by a proprietary Topo-1-based ADC platform that combines intelligent target-antigen selection with the SYNtecan E™ linker-payload technology and the exatecan payload. Exatecan is positioned as offering increased permeability, greater bystander effect, and lower resistance risk than other approved Topo-1 inhibitors (notably, it is not an MDR1 substrate). For NEOK002, the company has licensed Biocytogen's RenLite® bispecific antibody platform to access fully human bispecific antibody discovery capabilities. NEOK Bio has secured FDA IND clearance for both lead candidates and initiated Phase 1 clinical trials in May 2026.

The business model is pre-revenue and clinical-stage, with revenue mechanics expected to flow from future drug development and commercialization, including potential licensing transactions. To date, the company has raised approximately $100 million across two tranches led by ABL Bio ($75M Series A in November 2025 and $25M in March 2026). The company has no commercialized products, no distribution channels, and no announced customers or partnerships beyond its technology licensing relationship with Biocytogen and its strategic backing from ABL Bio. ABL Bio has publicly indicated that NEOK Bio is structured as a vehicle for potential M&A and a future Nasdaq listing.

Name

Neok Bio

Legal name

NEOK Bio, Inc.

Website

https://neokbio.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

NEOK Bio is a clinical-stage biotech developing bispecific antibody drug conjugates for solid tumor cancers. Founded in 2025 and backed by ABL Bio, the company is advancing two lead candidates, NEOK001 (B7-H3/ROR1) and NEOK002 (EGFR/MUC1), both in Phase 1 trials.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Bispecific antibody drug conjugates
• Oncology therapeutics
• Cancer drug development
• Antibody engineering platforms
• Topoisomerase inhibitor ADCs

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Drug Development and Commercialization: As a clinical-stage oncology therapeutics company, NEOK Bio is focused on developing bispecific ADC drug candidates through clinical trials with the goal of achieving regulatory approval and commercializing novel cancer treatments. The company is pre-revenue as of the current period, with initial clinical data expected in 2027.

Go-to-market motion1 record

Marketing channels3 records

Core offering

NEOK Bio is a clinical-stage oncology therapeutics company developing bispecific antibody drug conjugates (ADCs) for solid tumor cancers. It is advancing two lead drug candidates — NEOK001 (B7-H3/ROR1) and NEOK002 (EGFR/MUC1) — through Phase 1 clinical trials using a proprietary Topo-1-based ADC platform with SYNtecan E™ linker-payload technology and an exatecan payload. Both candidates target advanced solid tumors initially focused on thoracic, gastrointestinal, and gynecological cancers sensitive to Topo-1 inhibition.

Product overview

Neok Bio is a clinical-stage oncology therapeutics company developing a pipeline of differentiated bispecific antibody drug conjugates (ADCs) leveraging a novel Topo-1-based platform technology with proprietary SYNtecan E™ linker-payload technology. The company is advancing two lead bispecific ADC drug candidates: NEOK001 (targeting ROR1 and B7-H3) and NEOK002 (targeting EGFR and MUC1), both designed to improve outcomes for cancer patients by targeting proteins broadly expressed across tumor types with significant unmet needs, initially focusing on thoracic, gastrointestinal, and gynecological cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• NEOK001 Bispecific antibody drug conjugate (ADC) targeting B7-H3 and ROR1, in Phase 1 clinical development for advanced solid tumors (initially thoracic, gastrointestinal, and gynecological cancers sensitive to Topo-1 inhibition). Demonstrated superior in vivo efficacy compared to monovalent ADCs in preclinical studies; positioned to address limitations of single-target ADCs in selectivity, efficacy, and resistance.
• NEOK002 Bispecific antibody drug conjugate (ADC) targeting EGFR and MUC1, in Phase 1 clinical development for advanced solid tumors (initially thoracic, gastrointestinal, and gynecological cancers sensitive to Topo-1 inhibition). Built using Biocytogen's RenLite® bispecific antibody platform licensed to NEOK Bio; demonstrated superior in vivo efficacy compared to monovalent ADCs in preclinical studies.

Quantifiable outcome

• NEOK001 demonstrated superior in vivo efficacy compared to monovalent ADCs in preclinical studies
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• BiocytogencoreTechnology or Integration · 1 January 2024Biocytogen developed and licensed its bispecific antibody technology (RenLite® platform) to NEOK Bio in 2024 for the development of NEOK002, an EGFR/MUC1-targeting bispecific ADC. The FDA IND clearance for NEOK002 in 2026 validated Biocytogen's RenLite platform. This partnership provides NEOK Bio with access to fully human bispecific antibody discovery capabilities.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• AstraZeneca: Global pharma co-developer of Enhertu with Daiichi Sankyo. Relevant as a broad incumbent with significant Topo-1 ADC franchise investment that competes with NEOK Bio's payload and target strategy.
• Daiichi Sankyo: Global pharma company and pioneer of Topo-1-based ADCs (Enhertu, Dato-DXd). Comparable as the category-defining incumbent in Topo-1 ADC payloads — directly relevant to NEOK Bio's exatecan-based strategy.
• ABL Bio: Korean biotech parent of NEOK Bio and world-leader in bispecific antibody engineering. Directly comparable as both parent and peer — develops bispecific antibodies including ADCs and serves as NEOK Bio's primary technology and capital partner.
• Pfizer (Seagen): Pfizer acquired Seagen for its ADC platform and commercialized ADCs (Adcetris, Padcev). Broad incumbent in the ADC space with significant R&D investment in next-generation conjugates overlapping NEOK Bio's territory.

Direct peers

• ProfoundBio: Clinical-stage ADC developer focused on next-generation antibody drug conjugates for solid tumors. Closely comparable to NEOK Bio as a venture/strategic-backed ADC biotech pursuing differentiated payload and conjugation strategies in oncology.
• Mersana Therapeutics: Clinical-stage ADC company developing differentiated antibody drug conjugates for cancer. Highly comparable as a peer ADC-focused biotech developing novel linker-payload and targeting strategies for solid tumors.
• Duality Biologics: Developer of bispecific ADCs using proprietary linker-payload platforms for oncology. Directly comparable to NEOK Bio's bispecific ADC approach and SYNtecan E™-style platform architecture, with overlapping target and payload strategies.

Emerging players

• Pyxis Oncology: Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies. Comparable to NEOK Bio in stage and modality focus, though with a broader mix of ADC and immune-engager programs.
• Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating antibody-drug conjugates. Comparable as a peer clinical-stage ADC biotech, though with a distinct immune-stimulatory payload strategy.
• Biocytogen: Chinese antibody discovery platform company that licensed its RenLite® bispecific antibody technology to NEOK Bio. Directly comparable as a peer in bispecific antibody platforms and ADC enabling technologies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/NEOKBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neok Bio